Back to companies

Mesoblast Ltd: Premium Databases

Mesoblast Ltd Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Mesoblast Ltd Insights data

Headline Published Journalists
Showing 3 of 20+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 25 Feb 2022 Lorem
French COVID-19 study of mesenchymal stromal cell approach has enrollment goal altered to keep in line with COVID-19 case trends; 13 patients recruited so far, source says 08 May 2020 Manasi Vaidya
Athersys’, Pluristem’s and Mesoblast’s mesenchymal stromal cell therapies vie for efficacy in COVID-19 but best source and dosing strategy unclear; ability to adequately scale-up critical, experts say 16 Apr 2020 Manasi Vaidya
Investigator-led mesenchymal stromal cell study in ARDS starts including COVID-19 cases; five COVID-19 patients treated, investigator says 15 Apr 2020 Manasi Vaidya
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer